CELLTRION-HEALTHCARE
19.8.2022 04:49:05 CEST | Business Wire | Press release
Celltrion Healthcare announced today that the European Commission (EC) has approved Vegzelma™ (CT-P16), a biosimilar bevacizumab referencing EU-approved Avastin® , for the treatment of metastatic breast cancer, non-small cell lung cancer, advanced and/or metastatic renal cell cancer, metastatic carcinoma of the colon or rectum, ovarian cancer and cervical cancer.
“The European Commission’s approval of Vegzelma™ will increase access to treatment for patients living with certain types of cancer at an affordable price,” said Kevin Byoung Seo Choi, Senior Vice President and Head of Marketing Division at Celltrion Healthcare. “With proven similarities in efficacy and safety compared to the reference product Avastin® , Vegzelma™ will be available to treat some of the most commonly diagnosed cancers, which collectively affect hundreds of thousands of European patients each year.”
The EC approval of Vegzelma™ follows the recommendation for marketing authorisation issued by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) in June 2022.
Today’s approval is based on the totality of evidence, including the phase III pivotal trial in patients with metastatic or recurrent non-squamous non-small cell lung cancer. Results showed that, as a first-line treatment, Vegzelma™ is highly similar to the reference product in terms of efficacy, safety and pharmacokinetics.2
Vegzelma™ (CT-P16) is Celltrion’s third oncology biosimilar approved for use in the EU, following the approval of Truxima® (biosimilar rituximab) and Herzuma® (biosimilar trastuzumab). Vegzelma™ was also filed for regulatory approval with the U.S. Food and Drug Administration (FDA) in September 2021. Approval is expected during the third quarter of 2022.
- ENDS -
Notes to Editors:
About Celltrion Healthcare
Celltrion Healthcare is committed to delivering innovative and affordable medications to promote patients’ access to advanced therapies. Its products are manufactured at state-of-the-art mammalian cell culture facilities, designed and built to comply with the US FDA Current Good Manufacturing Practice (cGMP) and the EU GMP guidelines. Celltrion Healthcare endeavours to offer high-quality cost-effective solutions through an extensive global network that spans more than 110 different countries. For more information, please visit: https://www.celltrionhealthcare.com
About Vegzelma™ (CT-P16, biosimilar bevacizumab)
Vegzelma™ is an anti-cancer monoclonal antibody treatment biosimilar to Avastin® (bevacizumab). Vegzelma™ is a recombinant humanised monoclonal antibody which binds to VEGF, the key driver of vasculogenesis and angiogenesis, and thereby inhibits the binding of VEGF to its receptors Flt-1 (VEGFR-1), and kinase insert domain receptor (KDR) (VEGFR-2), on the surface of endothelial cells. Neutralising the biological activity of VEGF regresses the vascularisation of tumours, normalises remaining tumour vasculature, and inhibits the formation of new tumour vasculature, thereby inhibiting tumour growth.3 In the EU, Vegzelma™ is indicated for the treatment of patients with metastatic colorectal cancer, non-small cell lung cancer, metastatic renal cell carcinoma, ovarian cancer, advanced cervical cancer and metastatic breast cancer.
References
1 Avastin is a registered trademark of Genentech Inc.
2 Ohe Y et al., Randomized Phase III Study Comparing the Efficacy and Safety of CT-P16, a New Biosimilar, to Reference Bevacizumab (Avastin) In Patients With Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC). Proceedings: American Association for Cancer Research (AACR) Annual Meeting 2022; April 8-13, 2022 New Orleans, Louisiana.
3 European Medicines Agency Summary of Product Characteristics (SmPC), Avastin. Available at https://www.ema.europa.eu/en/documents/product-information/avastin-epar-product-information_en.pdf [Last accessed August 2022].
View source version on businesswire.com: https://www.businesswire.com/news/home/20220817005324/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Braskem to Showcase Sustainable Packaging Solutions at interpack 202628.4.2026 10:00:00 CEST | Press release
Braskem delivers scalable circular solutions that strengthen the packaging value chain and advance a lower‑carbon future. Braskem (B3: BRKM3, BRKM5, and BRKM6, NYSE: BAK, LATIBEX: XBRK) the largest polyolefins producer in the Americas, as well as a global market leader and pioneer producer of biopolymers on an industrial scale, will be at interpack 2026 in hall 9, booth A32, presenting packaging solutions made from bio-based, recycled and traditional polyolefins, enabling circular plastics, end-to-end. At interpack, Braskem will highlight I’m green™ bio‑based polyethylene grades specifically engineered for food‑contact applications, as well as Medcol V7040, a new grade for Healthcare and Hygiene. These innovations mark the first time Braskem has offered sustainably sourced sugarcane‑derived plastics for these segments. In an environment where packaging decisions are increasingly evaluated on both sustainability ambitions and business impact, Braskem positions itself as a materials part
Albion and Tecnotree Partner to Deliver Next-Generation VAS Platform for TELUS in North America28.4.2026 09:00:00 CEST | Press release
Albion, a leading provider of telecom managed services and solutions, today announced that TELUS has selected Albion, in partnership with Tecnotree, to deliver a next-generation Value-Added Services (VAS) platform, with an initial deployment of a voicemail application. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260428959214/en/ Albion and Tecnotree Partner to Deliver Next-Generation VAS Platform for TELUS in North America Under the engagement, Albion will deliver the solution leveraging Tecnotree’s proven VAS and digital services platform, supporting TELUS’ objectives to modernize service capabilities; enhance the customer experience; and ensure scalable, future-ready service delivery. As part of the deployment, Albion will provide end-to-end managed services, including platform operations, service assurance, and ongoing lifecycle management, ensuring high availability and performance for TELUS customers across North Ame
Budweiser Partners with Football Icons Erling Haaland and Jürgen Klopp to Unleash New “Let it Pour” Platform for FIFA World Cup 2026™28.4.2026 09:00:00 CEST | Press release
The platform extends across more than forty countries, bringing fans together with a new global film featuring Haaland and Klopp, limited edition apparel, and legendary fan experiences Today, Budweiser, the Official Beer Sponsor of the FIFA World Cup 2026™, unveiled its newest global football platform, “Let It Pour,” cracking open four years' worth of anticipation for the game’s biggest stage. Activating across more than forty countries, the global beer icon is supercharging celebrations with Bud FC fan events, The Bud Fan Store, and a new global film calling the world together to Let It Pour. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260428722336/en/ Budweiser Partners with Football Icons Erling Haaland and Jürgen Klopp to Unleash New “Let it Pour” Platform for FIFA World Cup 2026™ “For over four decades, Budweiser has been part of the celebrations that define the FIFA World Cup™, be it on the pitch, in bars, or wherev
Roquette Showcases Its Expanded Consumer Healthcare Capabilities at Vitafoods Europe 202628.4.2026 09:00:00 CEST | Press release
Experts will share insights on consumer ready innovations for everyday health at booth 3F112 Roquette, a global leader in plant-based ingredients, excipients and pharmaceutical solutions, will present its expanded portfolio at Vitafoods Europe 2026 which is taking place from May 5 to May 7 in Barcelona. Roquette’s offering is designed to help consumer healthcare brands stay future‑ready and accelerate consumer-centric innovations for everyday well-being. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260428405433/en/ Credits to Roquette As consumer expectations rise and shelf competition intensifies, dietary supplement and over-the-counter (OTC) brands, as well as contract development and manufacturing organizations (CDMOs), face growing pressure to deliver clean-label products that combine efficacy, strong sensory experiences, regulatory confidence, and speed to market. At Vitafoods Europe 2026, Roquette will demonstrate it
Microsoft and Postel: An Innovative New Data and AI-Driven Solution to Optimize Italian SMEs' Relationships with Their Customers28.4.2026 07:00:00 CEST | Press release
Microsoft and Postel, a Poste Italiane Group company, announce an evolution of their collaboration and of the agreements they have signed for the digitalization of Italian businesses, welcoming Audiencerate as technology partner in the Data and Direct & Digital Marketing space. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427013396/en/ The Marketing Data Platform combines AI-powered market intelligence, first-party data and omnichannel activation to help SMEs analyze market trends and historical campaign performance, turning insights into audiences and increasingly targeted future actions. The agreement provides for the distribution of an integrated platform that combines Postel's omnichannel physical-and-digital communication capabilities with Audiencerate'sdata intelligence functionalities and Microsoft's AI and Cloud solutions. The solution enables SMEs to leverage and activate their own data across the entire custom
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom